Lynda Charters

Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.

This study sheds light on the use of 0.05% atropine, which has been reported to be effective against myopia progression in some but not all studies.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Phase 3 shows epi-on oxygen CXL flattens pediatric keratoconus, improves vision, and stays well tolerated—now commercially available.

Caution advised by doctors and aviation safety experts

Meta-analysis finds refraction change better than axial length thresholds for tracking childhood myopia, urging growth-curve AL monitoring to flag retinal risk.

Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.

About 90% of patients are female with obesity and potential hormonal drivers

AI-powered polarized-light retinal imaging separates Alzheimer’s from ALS/FTLD deposits with 96% accuracy, promising low-cost early diagnosis.

This scenario emphasizes the need to gain an understanding of the role of hearing impairment in vision rehabilitation outcomes, particularly as they relate to functional independence.

Cases highlight faricimab’s dual VEGF/ANG2 action for severe diabetic macular edema—faster drying, better vision, longer intervals.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

Healthcare staff face splashes, aerosols, chemicals and lasers daily; ANSI-rated eye protection and better compliance prevent most workplace injuries.

Gene and cell therapies plus AI imaging tools accelerate breakthroughs for rare retinal diseases, spotlighting new trials for RP and Stargardt patients.

PULSAR post-hoc finds aflibercept 8 mg matches 2 mg for PCV, offering 12–16-week dosing and reduced injection burden.

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

The investigators wanted to assess the safety and feasibility of intravitreal injection of autologous CD34+ bone marrow stem cells (BMSCs) in eyes with vision loss from CRVO.

Real-world nAMD/DME care highlights durable anti-VEGF options and emerging TKIs and gene therapy to cut injection burden, improve vision, and reduce fluid.

New research links near work in dim light to myopia: accommodative pupil constriction may cut retinal illumination and speed worsening vision.

Clinicians emphasize screening, individualized care, and recognition of sex-based differences to prevent vision-threatening complications

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

Clear counseling and tailored lens choice reduce postoperative dissatisfaction

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

Reduced tobacco use and access to care are key components

Most eyes were fluid-free after 24 weeks with visual acuity increases observed in some.